Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 1/20 | 0.45 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.43 |
| ▸ | HPGD | P15428 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | GALR2 | O43603 | 1/20 | 0.43 |
| ▸ | MITF | O75030 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | XBP1 | P17861 | 1/20 | 0.43 |
| ▸ | CCR6 | P51684 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | FOS | P01100 | 2/20 | 0.43 |
| ▸ | JUN | P05412 | 2/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.43 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8398255 | 0.84 | AGTR1 (0.46) | AGTR1AGTR2ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL19453361 | 0.82 | AGTR1 (0.47) | AGTR1AGTR2ALDH1A1HPGDHSP90AA1 | |
| SCHEMBL11584008 | 0.79 | AGTR1 (0.43) | AGTR1AGTR2ALDH1A1HPGDLMNA | |
| SCHEMBL11584012 | 0.78 | AGTR1 (0.47) | AGTR1AGTR2HTTALDH1A1LMNA | |
| SCHEMBL25055275 | 0.78 | L3MBTL1 (0.40) | AGTR1AGTR2ALDH1A1LMNAKDM4E | |
| SCHEMBL1669584 | 0.78 | TSHR (0.48) | ALDH1A1HPGDLMNASMN1; SMN2HSP90AA1 | |
| SCHEMBL29906642 | 0.78 | TSHR (0.48) | ALDH1A1HPGDLMNASMN1; SMN2HSP90AA1 | |
| SCHEMBL9631461 | 0.77 | TSHR (0.44) | ALDH1A1HPGDLMNASMN1; SMN2POLB | |
| SCHEMBL24933235 | 0.77 | NR2F2 (0.56) | ALDH1A1LMNAPOLBXBP1NPSR1 | |
| SCHEMBL15170632 | 0.77 | LMNA (0.45) | AGTR1AGTR2ALDH1A1HPGDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170224687-A1 | COMPOUNDS FOR MODULATING TRPV3 FUNCTION | HYDRA BIOSCIENCES INC (US) | 2017-08-10 | — | — | US | disclosed |
| US-20170224687-A1 | COMPOUNDS FOR MODULATING TRPV3 FUNCTION | HYDRA BIOSCIENCES INC (US) | 2017-08-10 | — | — | US | disclosed |
| US-20170224687-A1 | COMPOUNDS FOR MODULATING TRPV3 FUNCTION | HYDRA BIOSCIENCES INC (US) | 2017-08-10 | — | — | US | disclosed |
| US-9486455-B2 | Compounds for modulating TRPV3 function | HYDRA BIOSCIENCES, INC. (US) | 2016-11-08 | — | — | US | disclosed |
| US-9486455-B2 | Compounds for modulating TRPV3 function | HYDRA BIOSCIENCES, INC. (US) | 2016-11-08 | — | — | US | disclosed |
| US-9486455-B2 | Compounds for modulating TRPV3 function | HYDRA BIOSCIENCES, INC. (US) | 2016-11-08 | — | — | US | disclosed |
| US-20140155417-A1 | COMPOUNDS FOR MODULATING TRPV3 FUNCTION | HYDRA BIOSCIENCES, INC. (US) | 2014-06-05 | — | — | US | disclosed |
| US-20140155417-A1 | COMPOUNDS FOR MODULATING TRPV3 FUNCTION | HYDRA BIOSCIENCES, INC. (US) | 2014-06-05 | — | — | US | disclosed |
| US-20140155417-A1 | COMPOUNDS FOR MODULATING TRPV3 FUNCTION | HYDRA BIOSCIENCES, INC. (US) | 2014-06-05 | — | — | US | disclosed |
| US-8552009-B2 | Substituted pyrimido 4.5-d pyrimidin-4-one compounds for modulating TRPV3 function | HYDRA BIOSCIENCES, INC. | 2013-10-08 | — | — | US | disclosed |
| US-20090018147-A1 | Compounds for modulating TRPV3 function | HYDRA BIOSCIENCES INC. (US) | 2009-01-15 | — | — | US | disclosed |
| US-20090018147-A1 | Compounds for modulating TRPV3 function | HYDRA BIOSCIENCES INC. (US) | 2009-01-15 | — | — | US | disclosed |
| WO-2008140750-A1 | COMPOUNDS FOR MODULATING TRPV3 FUNCTION | HYDRA BIOSCIENCES INC. (US) | 2008-11-20 | — | — | WO | disclosed |
| WO-2008140750-A1 | COMPOUNDS FOR MODULATING TRPV3 FUNCTION | HYDRA BIOSCIENCES INC. (US) | 2008-11-20 | — | — | WO | disclosed |
| EP-1954283-A2 | COMPOUNDS FOR MODULATING TRPV3 FUNCTION | Hydra Biosciences, Inc. (US) | 2008-08-13 | — | — | EP | disclosed |
| US-20070179164-A1 | Compounds for modulating TRPV3 function | HYDRA BIOSCIENCES, INC. (US) | 2007-08-02 | — | — | US | disclosed |
| US-20070179164-A1 | Compounds for modulating TRPV3 function | HYDRA BIOSCIENCES, INC. (US) | 2007-08-02 | — | — | US | disclosed |
| US-20070179164-A1 | Compounds for modulating TRPV3 function | HYDRA BIOSCIENCES, INC. (US) | 2007-08-02 | — | — | US | disclosed |
| WO-2007056124-A2 | COMPOUNDS FOR MODULATING TRPV3 FUNCTION | HYDRA BIOSCIENCES, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| WO-2007056124-A2 | COMPOUNDS FOR MODULATING TRPV3 FUNCTION | HYDRA BIOSCIENCES, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140155417-A1 | COMPOUNDS FOR MODULATING TRPV3 FUNCTION | TRPV3, TRPV1, TRPV4 | AGTR1 1303/4885AGTR2 902/4885GLA 3374/4885 |
| US-20090018147-A1 | Compounds for modulating TRPV3 function | TRPV3, TRPV1, TRPV4 | AGTR1 1303/4885AGTR2 902/4885GLA 3374/4885 |
| US-20070179164-A1 | Compounds for modulating TRPV3 function | TRPV3, TRPV1, TRPV4 | AGTR1 1303/4885AGTR2 902/4885GLA 3374/4885 |
| US-20170224687-A1 | COMPOUNDS FOR MODULATING TRPV3 FUNCTION | TRPV3, TRPV1, TRPV4 | AGTR1 1303/4885AGTR2 902/4885GLA 3374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.